These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32113829)

  • 1. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.
    Garcia-Rodriguez J; Fernandez-Gomez JM; Cozar JM; Miñana B; Gomez-Veiga F; Rodriguez-Antolin A; ;
    Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):156-163. PubMed ID: 32113829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Androgen deprivation therapy in advanced prostate cancer. Multicenter study.].
    Valencia-Guadalajara VJ; Martínez-Cayuelas L; Sarrió-Sanz P; Sánchez-Caballero L; Polo-Hernández R; Chillón-Sempere FS; Galán-Llopis JA; Garcés-Valverde M; Tenza-Tenza JA; Costa-Martínez A; García Serrado-Paumard D; Escudero-Fontana E; Tello-Royloa C; Verdú-Verdú LP; Bravo-López DF; Pérez Seoane-Ballester H; Pacheco-Bru JJ; Ortiz-Gorraiz MÁ
    Arch Esp Urol; 2020 Jul; 73(6):499-508. PubMed ID: 32633245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
    Warde P; Mason M; Ding K; Kirkbride P; Brundage M; Cowan R; Gospodarowicz M; Sanders K; Kostashuk E; Swanson G; Barber J; Hiltz A; Parmar MK; Sathya J; Anderson J; Hayter C; Hetherington J; Sydes MR; Parulekar W;
    Lancet; 2011 Dec; 378(9809):2104-11. PubMed ID: 22056152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.
    Miller ET; Chamie K; Kwan L; Lewis MS; Knudsen BS; Garraway IP
    Cancer Med; 2017 Jan; 6(1):163-172. PubMed ID: 27997745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?
    Niklas C; Saar M; Nini A; Linxweiler J; Siemer S; Junker K; Stoeckle M
    World J Urol; 2021 Sep; 39(9):3231-3237. PubMed ID: 33502558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
    Mikkelsen MK; Thomsen FB; Berg KD; Jarden M; Larsen SB; Hansen RB; Brasso K
    Scand J Urol; 2017 Dec; 51(6):464-469. PubMed ID: 28831860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer.
    Choi SY; Lim B; Chi BH; Lee W; Kim JH; Kyung YS; You D; Kim CS
    Medicine (Baltimore); 2021 Aug; 100(31):e26833. PubMed ID: 34397848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Androgen deprivation for advanced prostate cancer].
    Heidenreich A; Pfister D; Ohlmann CH; Engelmann UH
    Urologe A; 2008 Mar; 47(3):270-83. PubMed ID: 18273599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
    Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
    Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation.
    Seikkula H; Boström PJ; Seppä K; Pitkäniemi J; Malila N; Kaipia A
    BMC Urol; 2020 Mar; 20(1):25. PubMed ID: 32164671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.